secwatch.observer — SEC 8-K summary
======================================

Issuer:     Twist Bioscience Corp (TWST)
CIK:        0001581280
Form:       8-K
Filed at:   2022-11-18T23:59:59+00:00
Accession:  0001628280-22-030393
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Twist Bioscience reports FY2022 revenue $203.6M (+54% YoY); guides FY2023 revenue $261-269M
--------------------------------------------------------------------------------

- FY2022 revenue $203.6M, up 54% YoY; net loss $217.9M ($4.04/share) vs $152.1M loss in FY2021.
- Q4 FY2022 revenue $57.3M (up 51% YoY); net loss $51.1M ($0.91/share).
- Full year orders $226M, up 42% YoY; shipped 558,000 genes vs 372,000 in FY2021.
- FY2023 revenue guidance $261-269M; FY2024 target $350M.
- Promoted Patrick Finn, Ph.D. to president and COO; partnered with Illumina and PacBio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/twist-20221118.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-030393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer